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Abstract Turner syndrome (TS) is one of the most
common sex chromosome abnormalities. Affected individ-
uals often show a unique pattern of cognitive strengths and
weaknesses and are at increased risk for a number of other
neurodevelopmental conditions, many of which are more
common in typical males than typical females (e.g., autism
and attention-deficit hyperactivity disorder). This pheno-
type may reflect gonadal steroid deficiency, haploinsuffi-
ciency of X chromosome genes, failure to express
parentally imprinted genes, and the uncovering of X
chromosome mutations. Understanding the contribution of
these different mechanisms to outcome has the potential to
improve clinical care for individuals with TS and to better
our understanding of the differential vulnerability to and
expression of neurodevelopmental disorders in males and
females. In this paper, we review what is currently known
about cognition and brain development in individuals with
TS, discuss underlying mechanisms and their relevance to
understanding male-biased neurodevelopmental conditions,
and suggest directions for future research.
Keywords Turner syndrome . X chromosome .
Gonadal steroid . Estrogen
Many early onset neurodevelopmental disorders are male-
biased, that is they occur significantly more often in males
than females. These include autism spectrum conditions
(ASC; 4:1 to 9:1) (Baird et al. 2000; Chakrabarti and
Fombonne 2001), attention-deficit hyperactivity disorder
(ADHD; 3:1 to 5:1) (Szatmari et al. 1989; Moffitt 1990),
early onset persistent antisocial behavior (10:1) (Moffitt and
Caspi 2001), reading disability (2:1) (Liederman et al.
2005), language delay (2:1) (Salameh et al. 2002; Nelson et
al. 2006), and Tourette’s syndrome (9:2) (Wang and Kuo
2003). Intrinsic biological factors are likely to explain much
of the male-bias in these disorders, although sex differences
in exposure to environmental risks and/or protective
factors, societal expectations and values related to gender,
referral biases, or biased assessments are likely contributors
as well (Rutter et al. 2003). Specifically, X chromosome
effects and early exposure to gonadal hormones (androgens
and estrogens) appear to be the most important determi-
nants of sexual differentiation of the brain.
Two pathways to a sexually differentiated brain
First, experiments in animals clearly demonstrate that
gonadal hormones produced in fetal and neonatal life act
on the brain to produce sex differences in neural structure
and function (De Vries and Simerly 2002; Simerly 2002).
Gonadal hormones affect neural development by preventing
programmed cell death, influencing neural connectivity, and
altering neurochemical profiles (De Vries and Simerly
2002). For example, gonadal hormones modulate seroto-
nergic and γ-aminobutyric acid neurotransmission (Sumner
and Fink 1998; McCarthy et al. 2002), promote the
differentiation of vasopressin-expressing cells in the bed
nucleus of the stria terminalis and medial amygdaloid
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nucleus (Wang et al. 1993), increase cell genesis in the
developing hippocampus (Zhang et al. 2008), and interact
with brain-derived neurotrophic factor to maintain dendritic
length in the rat spinal nucleus of the bulbocavernosus
(Yang et al. 2004; Rasika et al. 1999).
Secondly, it is now well-established that genes on the sex
chromosomes are involved in sexual differentiation of the
brain independent of gonadal steroid exposure. This was
first suggested by studies showing sexual dimorphism in
cultures of rat embryonic (E14) brain stem in the absence of
sex steroids (Reisert and Pilgrim 1991), and later supported
by elegant studies of mice in which sex chromosomes and
gonadal sex were made independent by moving the SRY
(testis determining) gene from the Y chromosome to an
autosome (De Vries et al. 2002). Although most behavioral
and anatomic differences were determined by the presence
of ovaries or testes, some were dependent on chromosomes
alone. For example, both male and female mice with XY
sex chromosomes were more masculine (had a higher
density of vasopressin-immunoreactive fibers) than XX
mice in the lateral septum. Mice with a single X
chromosome (39,X) can also be generated (Davies et al.
2005) and show altered cognition in specific domains such
as fear reactivity and visuospatial attention (Davies and
Wilkinson 2006).
However, it may not be appropriate to directly extrapo-
late the results of studies in rodents to humans. Two
examples will demonstrate this difficulty. (1) In rodents,
prenatal/neonatal testosterone produces many of its mascu-
linizing effects after being aromatized to estrogen at the site
of action. Masculinizing effects are thus, primarily,
estrogen-receptor mediated. This is supported by experi-
ments using mice in which estrogen agonists mimic
testosterone effects on the sexual differentiation of behavior
and experiments in which aromatase inhibitors and anti-
estrogens inhibit masculinization of behavior (Mccarthy
1994). In contrast, studies in the rhesus macaque suggest
that the aromatization pathway is relatively unimportant in
primates—estrogen agonists have limited masculinizing
effects whereas the administration of a non-aromatizable
testosterone, dihydrotestosterone, exerts similar effects to
aromatizable testosterone (see Thornton et al. 2009 for
review). It is generally accepted that gonadal steroid-
mediated sexual differentiation of the brain in humans
relies primarily on the androgen rather than the estrogen
receptor. This is supported by studies showing that 46,XY
humans lacking a functioning androgen receptor (complete
androgen insensitivity syndrome) exhibit feminine behavior
(Hines 2002) while 46,XY humans with a dysfunctional
aromatase enzyme or those lacking a functioning estrogen
receptor exhibit masculine behavior (Grumbach and
Auchus 1999). (2) 45,X mice show no prenatal lethality,
appear anatomically normal, and are fertile (Ashworth et al.
1991). The phenotype in 45,X humans is markedly
different. Only 1% of human conceptuses with X monoso-
my survive to birth, and those that do exhibit a complex
phenotype including short stature, gonadal failure, and
other problems. During evolution, a pseudoautosomal
region (PAR) on the short arm of the ancestral X
chromosome has been retained in humans while most of
its genes have been lost or moved to autosomes in rodents
(Ross et al. 2005), contributing to the different phenotypes
in mice and humans with 45,X karyotypes. This review will
focus on the opportunities and challenges associated with
studying brain development and neurodevelopmental dis-
orders in individuals with loss of a sex chromosome.
What is Turner syndrome?
TS results from the complete loss of a sex chromosome (45,
X) or partial loss of the X chromosome that includes the
distal tip of its short arm. TS occurs in approximately 1 in
1,900 live female births, making it one of the most common
human chromosomal abnormalities (Nielsen and Wohlert
1991; Jacobs et al. 1974). Most individuals with TS have
short stature and gonadal dysfunction, and are at increased
risk for other problems such as structural cardiac and renal
defects, autoimmune disease, and learning disabilities.
There is a broad phenotype in TS, some of which is
explained by mosaicism. Mosaic individuals possess a 45,X
cell line and one or more additional cell lines. Most
commonly the additional cell line contains one normal X
and one structurally abnormal X or Y chromosome, but it
may be a normal 46,XX or 46,XY cell line (Savendahl and
Davenport 2000). Loss of ovarian function begins prena-
tally in TS, resulting in a postnatal developmental hormonal
milieu that is estrogen and androgen deficient. Therefore,
TS represents a powerful model for investigating both X
chromosome and gonadal steroid effects.
For many years, research on TS has primarily focused on
key medical issues, such as short stature and pubertal delay.
Only recently, have families and physicians caring for these
children begun to realize the major impact that neuro-
cognitive deficits have on their overall success and
happiness (Boman et al. 2004; Saenger et al. 2001). With
this realization comes a need for a better understanding of
brain structure and function in individuals with TS.
The cognitive phenotype(s)
The majority of individuals with TS are of normal
intelligence, but they may show an uneven pattern of
cognitive strengths and weaknesses. Areas which often
present difficulties include higher-order visual-spatial func-
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tions, visual memory, visuo-constructive abilities, and
visual attention, arithmetical abilities, executive functioning
(particularly inhibitory control, auditory attention, and
planning), social interaction, understanding facial expres-
sion, and specific aspects of language (verbal fluency,
complex syntactic knowledge, and articulation). There are
also areas of preserved and even strengthened function
including specific aspects of language (word knowledge,
receptive and expressive abilities, and verbal memory) and
rote memory (Rovet 2004; Ross et al. 2006; Christopoulos
et al. 2008).
Particularly relevant to the current discussion, females
with TS are at an increased risk for certain neurodevelop-
mental disorders. In one study, autism was observed in five
out of 150 individuals with TS (a rate of 3%) (Creswell and
Skuse 1999). Notably, this sample was recruited through a
national survey of TS and excluded individuals who had
been referred specifically for learning difficulties or
behavioral problems (including autistic behavior). At the
time this observation was published in the 1990s, the
prevalence of autism in the normal female population was
thought to be 1:10,000 (Lord et al. 1982), but it is now
estimated at 4:10,000 (Chakrabarti and Fombonne 2001;
Fombonne 2005; Baird et al. 2006), giving individuals with
TS a 75-fold increased risk of autism. ADHD was observed
in 24% of school-aged girls with TS which represents an
18-fold increase compared with girls in the general
population (prevalence of 1.3%) (Russell et al. 2006).
There may also be an increased risk for schizophrenia.
There are several published case reports (Kawanishi et al.
1997; Roser and Kawohl 2010) and TS occurs threefold
more frequently in schizophrenic females than in the
general female population (Prior et al. 2000). However, a
population-based screening study with sufficient power to
detect a relative risk of >2.4 for schizophrenia did not
reveal such a relationship (Mors et al. 2001). Finally,
despite the fact that most individuals with TS are of average
intelligence, one university center reported intellectual
disability in 11% of the 500 individuals with TS followed
in their clinic (Sybert and McCauley 2004). This is a 14-
fold increase when compared with the CDC estimated
population incidence of 0.8%.
Brain phenotype(s)
The cognitive phenotype(s) observed in individuals with TS
are assumed to reflect changes in neurobiological systems
which serve multiple functional domains. The results of
structural and functional neuroimaging studies in individu-
als with TS are consistent with this view. The most
consistently reported findings are a reduction in the volume
of the parietal lobe and an increase in the volume of the
amygdala (Cutter et al. 2006; Kesler et al. 2004; Molko et
al. 2004). The parietal lobe is involved in mental rotation of
objects, executive function, attention, and working memory,
domains which are often impaired in individuals with TS.
Functional imaging studies using positron emission tomog-
raphy have reported reduced activation in parietal regions at
rest (Elliott et al. 1996), and functional magnetic resonance
imaging studies have shown abnormal engagement of
parietal and prefrontal areas during specific tasks in females
with TS (Haberecht et al. 2001; Molko et al. 2003; Hart et
al. 2006; Kesler et al. 2006; Beaton et al. 2010). Diffusion
tensor imaging (DTI) has also revealed reduced fractional
anisotropy, often interpreted as reduced structural integrity,
in the superior longitudinal fasciculus, a major fiber tract
linking parietal and frontal regions and which includes the
“where” pathway of visuospatial cognition. The “where”
pathway appears to be more severely affected in TS than
the “what” pathway which runs through the inferior
longitudinal fasciculus (Holzapfel et al. 2006). The amyg-
dala has been implicated in the recognition of emotions
from facial expressions, with a particular role in processing
fear, in the detection of gaze direction and eye contact, and
in the mediation of arousal produced by affective stimuli. In
one study of females with TS, poorer performance on a task
of recognizing fearful facial expressions was correlated
with increased activation in the right amygdala. In contrast,
within control females poorer performance correlated
strongly with reduced activation of the right and left
amygdala (Skuse et al. 2005). Other brain regions where
volume decreases in TS have been reported include
occipital white matter, hippocampus, and thalamus. Volume
increases have been reported in the cerebellar gray matter,
orbitofrontal cortex, and superior and middle temporal
lobes (Cutter et al. 2006; Kesler et al. 2004). An MR
spectroscopy study of the temporal lobe suggests the
increase is the result of a developmental failure to prune
neurons (Rae et al. 2004).
While TS is a clearly defined genetic syndrome, there
are several different mechanisms which appear to contribute
to the cognitive and brain phenotypes which have been
observed. These include gonadal steroid deficiency, hap-
loinsufficiency of genes on the X chromosome, failure to
express imprinted genes (that is genes expressed from a
chromosome derived from one parent and not the other),
and the uncovering of X chromosome mutations (i.e., X-
linked recessive inheritance). We will explore these mech-
anisms next.
Mechanisms: gonadal steroid effects
The majority of females with TS have gonadal insufficiency
(Pasquino et al. 1997) and require exogenous sex steroids
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for induction of puberty. By observing whether sex steroid
replacement therapy rescues any of the TS cognitive or
brain phenotypes, the importance of sex steroids in the TS
phenotype can begin to be defined. Romans et al. (1998)
reported that performance on the Lafayette Pegboard
(Haaland and Delaney 1981), a motor planning task, was
better in older girls with TS (ages 17–22 years) compared
with adolescents (ages 13–16 years). They postulated that
the improvement could be the result of the cumulative
effects of estrogen replacement therapy. However, all study
subjects were estrogen treated, so a direct cause–effect
relationship could not be established.
More direct evidence for the positive effects of
estrogen therapy on brain function come from a
placebo-controlled, double-blind study of the effects of
estrogen and/or growth hormone (GH) on final adult
height in TS. Girls with TS were eligible to start the
study between the ages of 5 and 11 years. They were
randomly assigned to one of four treatment groups:
estrogen (ethinyl estradiol, 25 ng kg−1 day−1, by mouth
for girls ages 5–8 years; 50 ng kg−1 day−1 for girls ages 8–
12), GH 0.1 mg/kg, three times weekly, subcutaneously,
the combination of estrogen and GH, or placebo. All
subjects received an oral and an injected medication/
placebo. In the first study using this sample, cognition was
tested on 30 placebo-treated and 24 estrogen-treated TS
girls on one occasion at an average age of 8.1±0.6 years
after an average of 2.1±0.9 years (range, 0.5–3 years) in
the study (Ross et al. 2000a). About half of the children
were receiving GH, however, no significant interaction
effects for estrogen and GH were found. Therefore, the 2×
2 factorial design was merged into an estrogen-yes versus
estrogen-no comparison. A locally recruited age-matched
control group of 29 girls was also tested. As expected,
performance, but not verbal, IQ was significantly higher in
the controls than in either TS group. The estrogen-treated
TS group performed better than the placebo-treated TS
group on two tests of verbal memory (Children’s Word
List immediate and delayed recall (Tucker et al. 1974); p=
0.01 and 0.04) and one test of nonverbal memory (Digit
Span backwards (Wechsler 1974); p=0.02), although the
results were not significant after adjusting for multiple
comparisons. Performance on these tests was similar for
the estrogen-treated TS group and the control group.
In a second study, cognitive and motor functions were
tested in 23 placebo-treated and 24 estrogen-treated girls
with TS at an average age of 11.9±0.5 years after an
average of 4.0±2.1 years, and compared with 41 control
girls (Ross et al. 1998). Tests for general cognitive ability,
motor function, and handedness, nonverbal tasks for
measurement of processing speed, and behavior question-
naires were given. Performance IQ was significantly higher
in the control group. The speed of performance was
improved by estrogen treatment in TS subjects, although
the accuracy of timed spatial tasks was not consistently
changed. Estrogen was demonstrated to have a significant
positive effect on nonverbal processing speed (sum of times
required for motor-free visual perception test (Colarusso
and Hammill 1996), test of facial recognition (Benton et al.
1983), Money street map (Money et al. 1965), and
matching familiar figures (Kagan 1966)) and selective
aspects of speeded motor performance such as the Lafayette
pegboard (Haaland and Delaney 1981).
In 2002, Ross et al. (2002) compared cognitive function
of adult women with TS who were receiving estrogen
replacement therapy (e.g., estrogen and progesterone
sequentially and oral contraceptives) or who had apparently
normal ovarian function (as demonstrated by normal
menstrual cycles and adult breast development) with a
group of control women. The women with TS performed
more poorly than controls on measures of spatial/perceptual
skills (including gestalt closure (Kaufman 1983) and visual
object and space perception silhouettes (Warrington and
James 1991)), visual-motor integration (including Beery
visual-motor integration (Beery 1989) and Rey-copy
(Denman 1984; Waber and Holmes 1985)), affect recogni-
tion (Borod et al. 1990), visual memory (including Rey-
immediate and delayed recall (Denman 1984; Waber and
Holmes 1985), WMS-R (Wechsler 1987), and Warrington
Faces (Warrington 1984)), attention (TOVA (McCarney
1990)—% commission errors), and executive function
(Rey Figure Organization (Waber and Holmes 1985))
despite estrogen replacement therapy or presence of normal
menses. Based on these results they argued that the core
cognitive phenotype in TS is mediated by direct X
chromosome effects rather than sex steroid effects.
However, there was not an untreated TS control group
and age at initiation of sex hormone therapy, mode of
therapy, and adequacy of therapy were not reported. Sex
steroids can have both organizational effects (that is
permanent changes to the neural substrate, usually occur-
ring early in development) and activational effects
(transient changes, usually occurring later in life). Until
recently, initiation of estrogen therapy was often delayed
until age 15 years or later in an effort to maximize height.
If the women in this study did not receive early estrogen
replacement, the study cannot rule out a role for
organizational effects of estrogen in early puberty or
childhood. In addition, the predominant estrogen “replace-
ment therapy” in the USA has been conjugated equine
estrogens, which contains many estrogens, some of which
are not normally found in humans. It remains to be
determined if the positive effects of estrogen reported for
the children in the above studies or in children who
receive more physiologic estrogen replacement therapies
will impact cognitive and motor function in adulthood.
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Girls with TS have often been treated with oxandrolone,
a non-aromatizable androgen, to accelerate linear growth.
Ross et al. (2003) randomized TS girls, ages 10–14, to
receive oxandrolone or placebo for 2 years. Four cognitive
domains were evaluated (verbal abilities, spatial cognition,
executive function, and working memory) at baseline, 1,
and 2 years of the study. Three of the four domains studied
did not differ between the groups. However, verbal working
memory was better in the oxandrolone-treated group. A
similar result was observed in a randomized, double-blind,
placebo-controlled study of oral methyl testosterone treat-
ment for 1 year in TS women between 17 and 27 years of
age. Methyl testosterone improved verbal memory as well
as attention and reaction time, but did not affect spatial
cognition or executive function (Zuckerman-Levin et al.
2009). Oxandrolone has also been reported to reduce
problem behavior (as measured by the Child Behavior
Checklist (Achenbach 1991)) in girls in which mean age at
initiation was 10 years and mean age at discontinuation was
15 years (Menke et al. 2010).
Absent from the current research literature are studies on
the possible effects of prepubertal gonadal steroid deficien-
cy in girls with TS. Little definitive data on sex steroid
regulation in prepubertal children has been established due
to the absence of sensitive, commercially available assays.
Klein et al. (1994), using a highly sensitive bioassay, were
the first to determine that estrogen levels in prepubertal
girls are significantly higher than those of prepubertal boys.
Recently, however, sensitive, very specific, and highly
reproducible assays for estradiol and other sex steroids
using gas chromatography combined with mass spectrom-
etry or liquid chromatography tandem mass spectrometry
(LC-MS/MS) methodologies have become commercially
available. These assays are currently considered the gold
standard for sex steroid measurements (Albrecht and Styne
2007; Rahhal et al. 2008).
Recently, LC-MS/MS was used to compare multiple sex
steroids, including estradiol, in the serum of prepubertal
boys and girls ages 6–11.5 years. 17-β estradiol levels in
prepubertal boys were undetectable or extremely low
(median, ≤3.7 pmol/l), whereas levels in prepubertal girls
were significantly higher (median, 9.6 pmol/l) (Courant et
al. 2010). While estrogen levels have not been directly
measured in young girls with TS, one would expect the
majority to be estrogen deficient because of early, acceler-
ated follicular degeneration, an assumption which is
supported by markedly elevated FSH levels in most young
girls with TS (Fechner et al. 2006).
Also lacking in the research literature are MRI studies
directly investigating the role of estrogen or androgen on
the brain in TS. Only one study has addressed effects of
androgen supplementation on the brain. Cutter et al. (2006)
reported no differences in brain structure between 12
women who received oxandrolone and 15 who did not,
using a voxel-based morphometry method. No MRI studies
have assessed estrogen effects on the brain in TS. Assessing
estrogen effects on the brain is complicated by the
multitude of estrogen replacement regimens, including the
form of estrogen, mode of delivery, timing of initiation,
timing of dose acceleration, and addition of progestational
agents. Finally, no studies have assessed the impact of sex
steroid hormone replacement on psychiatric diagnosis or
severity of symptoms in those subgroups of TS females
diagnosed with ASC, intellectual disability (ID), ADHD, or
schizophrenia. It is of particular interest to note that three
randomized double-blind placebo-controlled trials and one
open-label study have shown that giving estradiol in
addition to traditional antipsychotic medications is associ-
ated with significant reduction of symptoms in women with
schizophrenia (Kulkarni 2009). Thus, it is plausible that
estrogen deficiency could increase the risk for schizophre-
nia in women with TS. One of the most marked sex
differences in the general population of individuals with
schizophrenia is a later age of onset in females than in
males, and it has been hypothesized that this is the result of
the protective actions of estrogen. If this is the case, risk for
schizophrenia within the TS population could vary with age
at initiation of estrogen therapy.
Mechanisms: haploinsufficiency of X chromosome genes
Although typical females have two X chromosomes, only
one of these is generally active. X chromosome inactivation
(the process by which one X is suppressed while the other
remains active) acts to negate the “dosage” difference in X
chromosome genes between males and females. However,
some genes on the human X chromosome continue to be
expressed from the “inactive” X. It has been estimated that
15–20% of genes are expressed from the inactive X (Craig
et al. 2004; Carrel and Willard 2005), although a recent
gene expression study suggested that only 5% of X-linked
genes actually achieve significantly higher expression
levels in females compared with males (Johnston et al.
2008). For the subset of X chromosome genes that escape
inactivation, females with TS will be haploinsufficient and
this may contribute to the cognitive phenotype and risk for
other neurodevelopmental disorders. One approach to
identify the particular genes involved is to compare
phenotypes of individuals missing various portions of one
sex chromosome, a strategy known as deletion mapping.
Ross et al. (2000b) and Zinn et al. (2007) used this
approach. For their phenotype of interest, they developed a
“Turner Syndrome Cognitive Summary Score” or TSCS,
which was based on discriminant function analysis of a
wide range of cognitive tests. While working memory,
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attention-impulse control, and executive function tests are
included, the final score is heavily weighted towards
visuospatial abilities. Results from their initial study, which
included both children and adults and used TSCS score as a
binary variable, suggested that Xp22.3 contains one or more
genes that influence TSCS (Ross et al. 2000b). A subsequent
study which focused only on adults and used TSCS as a
quantitative variable confirmed that deletion of Xp22.3 was
sufficient to cause this neurocognitive phenotype (Zinn et al.
2007). This region contains 31 annotated genes and the
authors highlighted two genes, STS and NLGN4X as
potential candidates. STS has been implicated in GABAA
receptor function (Majewska 1992) and visuospatial attention
in a mouse model of TS (Davies et al. 2007) and has also
been linked to ADHD in humans (Doherty et al. 2003; Kent
et al. 2008; Brookes et al. 2008). NLGN4X mutations have
been associated with ASC and X-linked ID (Chakrabarti et
al. 2009; Daoud et al. 2009; Jamain et al. 2003; Laumonnier
et al. 2004; Lawson-Yuen et al. 2008; Talebizadeh et al.
2006; Yan et al. 2005; Qi et al. 2009). However, it should be
noted that the smallest deletion associated with the neuro-
cognitive phenotype did not include either of these genes,
but only PLCXD1, GTPBP6, PPP2R3B, and SHOX, none of
which have been previously implicated in cognition or risk
for neurodevelopmental disorders.
A similar strategy was applied by Good et al. (2003) to
explore the cause of decreased recognition of fear in females
with TS. A genetic locus (no greater than 4.96 Mb in size)
was identified at Xp11.3 that affected fear recognition and
amygdala volume. The authors hypothesized that the genes
for monoamine oxidase A (MAOA) and B (MAOB), which
are located in this region and are involved in the oxidative
deamination of several neurotransmitters, including dopa-
mine and serotonin, could be responsible for the phenotype.
Subsequently, this group used regression-based association
mapping to identify potential candidate genes within this
region. They reported a single-nucleotide polymorphism in
EFHC2 which explained over 13% of the variation in fear
recognition within women with TS (Weiss et al. 2007).
However, a later study by a separate lab failed to replicate
this finding (Zinn et al. 2008).
In conclusion, haploinsufficiency of X chromosome
genes is likely to play a role in the cognitive phenotype
of TS. While several interesting candidate genes have been
proposed, no genes have been conclusively identified as
responsible for any aspect of the cognitive phenotype.
Mechanisms: failure to express parentally imprinted
genes
Genomic imprinting refers to a process by which genetic
effects are influenced according the whether the genes are
transmitted through the father or the mother (Skuse 2000).
Ordinarily this would not result in sex differences, but it
will do so if the imprinting affects the X chromosome. This
possibility has been most extensively studied in relation to
social and communicative impairment in TS. In 1997,
Skuse et al. reported that social difficulties were more
pronounced in females with TS who inherited a maternal X
chromosome than in those who inherited a paternal X
chromosome. Typical females inherit an X chromosome
from both parents (XpXm), and typical males inherit only
a maternal X (XmY). The authors hypothesized that a gene
expressed on the paternal X enhances social cognition and
is a protective factor against ASC (Skuse et al. 1997).
Shortly afterwards, Creswell and Skuse reported five cases
of autism from an unselected sample of 150 subjects with
TS (Creswell and Skuse 1999). All the affected cases were
Xm or had a structurally abnormal paternal X. While this
was certainly an exciting finding, it should be kept in
mind that 77% of TS females are Xm, while only 23% are
Xp, meaning that by chance alone one would expect to
find autism in association with Xm more often than with
Xp. In addition, all of the autism cases in that report had
low verbal IQ scores, despite the fact that intelligence is
usually in the average range in TS, raising the possibility
that the autism was secondary to ID. The male-to-female
sex ratio for ASC is only 2:1 in individuals with moderate
to severe ID in contrast to 5.5:1 in individuals with
average intelligence (Fombonne 2005). It is also notable
that some of the autism cases had a structurally abnormal
paternal X. TS individuals with small ring X chromo-
somes often have a severe phenotype that is not typical of
TS and includes intellectual disability. In these individu-
als, the loss of the XIST gene, which is involved in
causing X inactivation, may allow for normally inacti-
vated genes to be expressed, resulting in functional
disomy (Kubota et al. 2002). Finally, Henn and Zhang
(1997) raised the possibility that the presence of residual
Y chromosome sequences in a subset of cells in the brain
could explain the greater vulnerability of Xm TS females
to social dysfunction, but this hypothesis is untestable
without access to brain tissue.
Despite many uncertainties, the role of parentally
imprinted genes in TS and in sex-biased neurodevelopmen-
tal disorders is an extremely exciting avenue for future
research. Imprinting effects are now routinely tested for in
MRI studies in individuals with TS and have been observed
for the superior temporal gyrus (Kesler et al. 2003),
occipital white matter, cerebellar gray matter (Brown et al.
2002), hippocampus, thalamus, and caudate (Cutter et al.
2006). Imprinting effects have also been reported for non-
behavioral aspects of the TS phenotype, including body
mass index, lipid levels, kidney malformations, and ocular
abnormalities (Sagi et al. 2007).
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Mechanisms: X-linked recessive inheritance
and functional disomy
Like typical males, females with TS are at an increased risk of
X-linked recessive conditions, including ID, as a second X is
not present to balance the effects of the abnormal gene. In the
general population, more than 10% of cases of ID show an X-
linked pattern of inheritance, involving mutations in over 90
different genes. On the flip side, the subgroup of individuals
with TS at highest risk for ID are those with small ring Xs that
fail to undergo inactivation, resulting in functional disomy for
normally inactivated genes (Kubota et al. 2002). Intriguingly,
some X-linked recessive conditions may result in the loss of
the diseased X during mitosis, producing mosaic TS. This
has recently been reported for female embryos carrying the
full fragile X mutation (Dobkin et al. 2009).
Future directions: deeper into the brain
While neuroimaging has and will continue to advance our
understanding of neurodevelopment in individuals with TS,
current techniques are not capable of identifying the neuro-
developmental processes which underlie observed changes in
tissue volumes or DTI parameters. Structural and molecular
biology techniques applied to post-mortem brains comple-
ment neuroimaging approaches by identifying alterations in
the number or volume of different cell types and alterations of
pathway-related genes and proteins (Schmitt et al. 2008).
Unfortunately, post-mortem studies in individuals with TS
are extremely scarce and date back several decades. Based
on the limited studies available, there appears to be overall
decreased cortical organization, possibly due to neuronal
migration deficits (Molland and Purcell 1975; Gullotta and
Rehder 1974; Urich 1979; Reskenielsen et al. 1982).
Significantly, more information could be gained from post-
mortem samples given technical advances and the develop-
ment of more targeted hypotheses. For example, the
frequency of cell line mosaicism and differences in gene
expression within specific regions of the brain could be
determined. Comparison to post-mortem findings in other
neurodevelopmental conditions could clarify whether there is
true etiological homology between conditions or if very
different mechanisms produce similar behavioral outcomes.
Brain banks play an important role in psychiatric research,
particularly in the schizophrenia field, and it worth consid-
ering whether this strategy can be applied in the study of TS.
Future directions: deeper into the genome
One of the most striking features of the TS population is the
extreme variability in phenotype. We have already dis-
cussed some genetic aspects of TS that may help explain
this variability, including parental origin of X chromosome,
cell line mosaicism, imprinting, and the uncovering of X-
linked mutations. Variability could also result from the
genetic background in which loss of the second sex
chromosome occurs. Applying genome-wide analysis
approaches to individuals with TS and comparing those
with or without comorbid neurodevelopmental disorders
could be a powerful strategy for identifying genetic risk
factors on the autosomes, although limited sample sizes
would be a definite issue. An alternative approach would be
to select candidate genes which have emerged from
genome-wide studies of relevant neurodevelopmental dis-
orders and investigate these intensively within TS samples.
For example, mutations in genes coding for synaptic cell
adhesion molecules and their related proteins, such as
neurexin-1 (NRXN1) and contactin-associated protein-like 2
(CNTNAP2), have been reported in association with ASC
(Feng et al. 2006; Szatmari et al. 2007; Kim et al. 2008;
Bakkaloglu et al. 2008; Rossi et al. 2008), schizophrenia
(Kirov et al. 2008; Walsh et al. 2008; Rujescu et al. 2009;
Stone et al. 2008; Kirov et al. 2009; Need et al. 2009;
Friedman et al. 2008), ADHD (Elia et al. 2010), and ID
(Friedman et al. 2008; Zweier et al. 2009). Genetic and
epigenetic changes on the remaining X could also contrib-
ute to phenotypic variability, with some individuals capable
of compensating for the lost alleles by upregulating the
remaining ones. X chromosome genes including NLGN4,
NLGN3, MECP2, and PTCHD1 have been linked to ASC
(Daoud et al. 2009; Jamain et al. 2003; Laumonnier et al.
2004; Lawson-Yuen et al. 2008; Talebizadeh et al. 2006;
Yan et al. 2005; Pinto et al. 2010; Noor et al. 2010; Shinawi
et al. 2009; Carney et al. 2003; Lam et al. 2000) and would
be worthy of detailed investigation in TS. Intriguingly, post-
synaptic neuroligins (which include NLGN4 and NLGN3)
interact with the presynaptic neurexins (such as NRXN1) to
form trans-synaptic associations. Both groups are required
for the maturation of glutamatergic excitatory and
GABAergic inhibitory synapses (Leone et al. 2010). We
have already stated the potential value of post-mortem gene
expression studies in brain, but similar approaches in more
accessible tissues would also be of interest.
Future directions: going earlier in development
The majority of neuroimaging and behavioral studies of TS
carried out to date have focused on older children and
adults. Thus, they cannot address when in development the
reported differences emerge. A better knowledge of when
brain development is altered could help pinpoint the cause
of functional changes and identify critical periods for
intervention. In addition, older children and adults have
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often been exposed to many years of therapies such as GH
and estrogen that are likely to impact neurodevelopment.
Treatment may have produced some of the observed neural
differences or it may have minimized or eliminated neural
differences present before treatment began. It is now
recommended that GH therapy (used to improve or
normalize height) be considered as soon as growth failure
is demonstrated. In the recent “Toddler Turner Study”
study, girls ages 9 months to 4 years with TS (mean age=
2 years) were randomized to GH therapy or no therapy.
Girls in the GH group achieved a height 1.6 SD above that
of the no therapy group after 2 years, and averaged just 0.3
SD below the mean height for girls in the general
population (Davenport et al. 2007). Since growth failure
typically begins in infancy, many girls with TS are now
being treated with GH beginning in the first 2 years of life.
However, the effect of GH on brain development in young
children is unknown. Estrogen therapy is now delayed until
the time of normal puberty and the effect of estrogen on
brain development in the first few years of life is unknown.
Studies of brain development in TS, prior to long-term
hormonal therapy, will be critical in determining the
potential role of standard hormone therapies in ameliorating
or producing the brain changes observed in older females
with TS. This information will have important implications
for determining appropriate timing, type, and dosage of
hormone therapies.
At present, the only neurocognitive and psychosocial
data for this group comes from the Lilly “Toddler Turner
Study” in which young girls with TS were followed at
4 months intervals for 2 years. At baseline, 1, and 2 years
neurocognitive and psychosocial studies were performed.
On the Mullen Scale of Early Learning (Mullen 1995), this
TS population was significantly below the normative means
for the five subtests (Fine-Motor, Gross Motor, Receptive
Language, Expressive Language, and Visual Reception),
with approximately 20% of the sample being more than
2SDs below the mean on the overall score. On a measure of
social-behavioral functioning, the Vineland Social-
Emotional Early Scales (Sparrow and Balla 1998), the TS
group fell largely at the lower end of the average range of
functioning, with the scores for Interpersonal Relationships,
Play and Leisure, and the Composite being significantly
below the normative means. On the Carey Temperament
Scale (Carey and McDevitt 1995), the girls with TS were
described as less persistent, more cautious in their approach
to new situations, and slower to adapt to these situations
(Hooper et al. 2005). The same study provides preliminary
evidence that the trajectory of brain development in girls
with TS from birth to 2 years of age may be considerably
different that those of typical females. They compared
historical birth length, weight and head circumference (HC)
values corrected for gestational age <37 weeks to those
measured at study entry. While mean length and weight
fell markedly from birth to study entry (∼1 SD), mean
HC was relatively smaller at birth (−1.0±1.2 SD) and
normalized by study entry (−0.0±1.2 SD), suggesting
accelerated brain growth in early life (Davenport et al.
2002). Interestingly, an accelerated increase in HC in the
first year of life has also been reported for children with
autism (Hazlett et al. 2005).
Future directions: addressing the role of clinical
experience and treatment on neurodevelopmental
outcome
The effects of X chromosome monosomy is not restricted to
the brain, but impacts almost every organ system in the
body. Therefore, individuals with TS may be exposed to a
wide range of medical issues and treatment paradigms
which could potentially affect neurodevelopment. Despite
this reality, it is unusual for published studies of cognition,
behavior, or neuroimaging in individuals with TS to include
detailed information on the medical history of the partic-
ipants. In this review, we will highlight four common
medical issues in this population and how they might
impact brain development. These include growth failure
(and subsequent treatment with GH), cardiovascular mal-
formations (and related surgeries), thyroid autoimmunity,
and hearing issues.
Short stature is the most common physical finding in TS,
with untreated individuals achieving an average adult
stature of 20 cm (8 in.) shorter than would be predicted
based on parental height (Ranke and Grauer 1994). Growth
failure results from haploinsufficiency of the short-stature
homeobox-containing gene which belongs to a family of
homeobox genes, critical transcriptional regulators of early
development (Rao et al. 1997). Psychosocial functioning in
girls with TS does not appear to be strongly related to
stature, despite concerns that short stature may result in
stigmatization, juvenilization, and decreased quality of life
(QOL) (Sandberg and Voss 2002). The standard treatment
for growth failure is the administration of supraphysiolog-
ical doses of GH (Davenport 2006) However, the reported
impact of GH on QOL has been relatively unimpressive.
For example, Amundson et al. (2010) recently reported that
in a group of 111 adults with TS, previous GH treatment
was associated with less pain but did not mitigate the
increased social isolation of this group. GH could have a
direct effect on brain development, especially in younger
children. Information regarding the impact of circulating
GH levels and of GH supplementation in particular on
human structural brain development is extremely limited,
but a direct effect of circulating GH on brain structure is
possible, given that GH is found in the brain and CSF and
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GH receptors are located in multiple brain regions
including the choroid plexus, hippocampus, hypothalamus,
amygdala, and pituitary (Nyberg 2000). Circulating GH
does not passively diffuse across the blood–brain barrier
(BBB), but it may be transported across the BBB via a
receptor-mediated mechanism (Coculescu 1999). GH may
also exert effects on brain development via insulin-like
growth factor 1 (IGF-1), which appears to be actively
transported across the BBB (Gunnell et al. 2005). IGF-1
receptors are also present in the brain with the greatest
density of receptors localized to the cortex and hippocam-
pus (Adem et al. 1989). Rodent studies demonstrate that
IGF-1 plays a crucial role in neurogenesis, myelination,
synaptogenesis, and dendritic branching. Transgenic mice
which overexpress IGF-1 have increased brain size, while
those with IGF-1 deletions have reduced brain size (Carson
et al. 1993; Beck et al. 1995). Thus far only one structural
MRI study in TS has addressed this issue. Cutter et al.
(2006) reported that adult women with TS who did not use
GH had significantly decreased gray matter volume
bilaterally in the parieto-occipital and posterior temporal
lobes and basal ganglia, compared with those who did not
take GH.
Cardiovascular malformations are common in indi-
viduals with TS. In an echocardiographic study of 200
individuals, aortic coarctation with or without a bicuspid
valve was present in 14%, bicuspid valve alone in 10%,
aortic stenosis and/or regurgitation in 5%, and other
structural defects such as hypoplastic left heart, atrial
septal defect, and ventricular septal defect in 10%
(Sybert 1998). Such malformations represent an indepen-
dent risk factor for altered brain development. Newborns
with congenital heart disease (CHD) show a high
frequency of acquired white matter injury. Significant
problems pertaining to intelligence, neuropsychological
development, and social cognition (Bellinger 2008) have
been documented for many children with CHD who have
undergone surgery. Neurobehavioral and neurological
abnormalities are also common in children with CHD
prior to surgery (McQuillen and Miller 2010) and may
result from the same developmental event(s) that caused
the cardiac defect or from damage incurred prenatally
from altered blood flow or oxygenation. For example,
coarctation/aortic arch hypoplasia increases the risk for
microcephaly at birth 2.8-fold.
Individuals with TS are at increased risk for
autoimmune disorders and the risk increases with age
(Mortensen et al. 2009). Thyroiditis is the most common
autoimmune disorder and has been reported as early as
4 years of age. In a study of 84 children with TS who were
followed longitudinally for an average of 8 years, 20
developed hypothyroidism and two developed hyperthy-
roidism (Livadas et al. 2005). Hypothyroidism has
profound effects on neurodevelopment and may have
more subtle effects when present subclinically or tran-
siently (Williams 2008).
Sixty to 80% of individuals with TS suffer from
conductive hearing loss because of chronic otitis media
(Hultcrantz 2003). This may be related to having a short,
horizontally oriented eustachian tube which results in poor
drainage and ventilation of the middle ear space. Ear
infections are especially common in the first few years of
life. For example, in the “Toddler Turner Study”, at the
baseline study visit (mean age=2 years), 26% had
tympanostomy tubes present, another 64% had evidence
of abnormal middle ear function, and 27% had abnormal
hearing in one or both ears (Davenport et al. 2010). In
addition, progressive sensorineural hearing loss with a
unique dip in the 1.5–2 kHz region and/or a high frequency
loss (above 8 kHz) may present very early and necessitate
the use of hearing aids in childhood. Early hearing
difficulties could clearly impact the development of
language and socialization and should be documented in
research studies as well as dealt with quickly in the clinic.
Conclusions
Turner syndrome is one of the most common sex
chromosome abnormalities and as such represents an
important health problem. In addition, studies carried out
in this population can help us model the effects of both sex
hormones and genes on the X chromosome in early brain
development and thereby better our understanding of the
differential vulnerability to and expression of neurodeve-
lopmental disorders in males and females. This research
paradigm has already produced novel theories, such as the
X-linked parental imprinting theory of autism. However,
disentangling the contribution of steroid hormones and
genetic factors is challenging. We suggest several directions
for future research to help resolve these issues including
carrying out neuroimaging studies at earlier time-points,
pursuing post-mortem studies with the latest structural and
molecular biology techniques, applying modern genomics
strategies, and the routine consideration and reporting of
medical history.
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